ucose lowering effect. To what extent this beneÔ¨Åt can
also be observed in those with type 1 diabetes mellitus, in
whom glucose management with these drugs only has a
limited (SGLT-2 inhibitors) or no (GLP-1 agonists) role to
play, remains to be established. In individuals with an
eGFR < 30 mL/min/1.73m2, these drugs are contraindicated. Therefore,